Results 201 to 210 of about 180,429 (290)
Ileocecal CD5-Positive Diffuse Large B-Cell Lymphoma Presenting with Acute Obstructive Symptoms: A Case Report. [PDF]
Kashiwagi J +14 more
europepmc +1 more source
Summary This second part of the S3 guideline on the diagnosis and treatment of alopecia areata (AA), presents key recommendations on topical and systemic therapy, quality of life and support services. The first part of the guideline, published separately, covers the definition and content of epidemiology and diagnosis as well as comorbidities, risk and
Ulrike Blume‐Peytavi +13 more
wiley +1 more source
Enhancing Immunotherapy in Diffuse Large B-Cell Lymphoma: The Synergistic Potential of Metabolic Checkpoint Inhibitors and Immunomodulation. [PDF]
Rajendraprasad MK, Riches JC.
europepmc +1 more source
SAMHD1 regulates intracellular dNTP pools, influencing lentiviral transduction, gene therapy efficiency, and disease progression in pediatric hematological malignancies. Integrated bioinformatics and targeted strategies, including CRISPR and pharmacological inhibition, highlight its therapeutic potential.
Waseem Alzamzami
wiley +1 more source
Clinical Characteristics and Prognostic Prediction of Secondary Solid Malignancies in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. [PDF]
Zhang L +7 more
europepmc +1 more source
ABSTRACT Adult hemophagocytic lymphohistiocytosis (HLH) is a rare, life‐threatening syndrome triggered by various conditions. A nationwide study of the incidence and outcomes of HLH in Denmark over 23 years (2000–2023) was performed. Adults (≥ 18 years) with HLH and triggering diseases were identified in the Danish National Patient Registry and/or the ...
Mads Okkels Birk Lorenzen +8 more
wiley +1 more source
Spatial transcriptomics unveils immune cellular ecosystems associated with patient survival in diffuse large B-cell lymphoma. [PDF]
Diaz-Herrero A +11 more
europepmc +1 more source
ALK Expression in Nerve Sheath Myxoma: A Potential Diagnostic Pitfall
Journal of Cutaneous Pathology, EarlyView.
Daniel Cole +6 more
wiley +1 more source
ABSTRACT Patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who progress to the third‐line setting face a lack of standardized treatment, despite the presence of multiple available therapies. In this context, antibody–drug conjugates represent a relatively new class of anticancer agents; among them, loncastuximab tesirine is ...
Francesca Bonello +7 more
wiley +1 more source
Rectal diffuse large B-cell lymphoma misdiagnosed as bleeding cancer in an elderly patient. [PDF]
Zhong Y +5 more
europepmc +1 more source

